Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.085
-0.035 (-3.11%)
Nov 21, 2024, 1:39 PM EST - Market open

Company Description

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.

The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults.

The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.

Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Heron Therapeutics, Inc.
Heron Therapeutics logo
Country United States
Founded 1983
IPO Date Aug 26, 1987
Industry Biotechnology
Sector Healthcare
Employees 126
CEO Craig Collard

Contact Details

Address:
4242 Campus Point Court, Suite 200
San Diego, California 92121
United States
Phone 858 251 4400
Website herontx.com

Stock Details

Ticker Symbol HRTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000818033
CUSIP Number 427746102
ISIN Number US4277461020
Employer ID 94-2875566
SIC Code 2834

Key Executives

Name Position
Craig Alexander Collard Chief Executive Officer and Director
Ira Duarte Executive Vice President and Chief Financial Officer
Dr. William P. Forbes Pharm. D., Pharm.D. Executive Vice President and Chief Development Officer
Ryan Craig Vice President of Marketing
Sean T. Ristine Senior Vice President of Human Resources
Robert Sullivan Senior Vice President of Oncology Care Franchise and Commercial Operations
Brett Fleshman Chief Business Officer
Jeff Cohn Executive Director, Assistant General Counsel and Assistant Secretary

Latest SEC Filings

Date Type Title
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 8-K Current Report
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 6, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report
Jul 2, 2024 8-K Current Report